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Signiﬁcance of p53-binding protein 1 nuclear foci in uterine cervical lesions: endogenous
DNA double strand breaks and genomic instability during carcinogenesis
Aims: A defective DNA damage response can result in
genomic instability (GIN) and lead to transformation to
cancer. As p53-binding protein 1 (53BP1) localizes at
the sites of DNA double strand breaks (DSBs) and
rapidly forms nuclear foci (NF), the presence of 53BP1
NF can be considered to be an indicator of endogenous
DSBs reﬂecting GIN. Our aim was to analyse the
presence of DSBs by immunoﬂuorescence for 53BP1
expression in a series of cervical lesions, to evaluate the
signiﬁcance of GIN during carcinogenesis.
Methods and results: Atotalof80archivalcervicaltissue
samples, including 11 normal, 16 cervical intraepithe-
lial neoplasia (CIN)1, 15 CIN2, 24 CIN3 and 14
squamous cell carcinoma samples, were analysed for
53BP1 NF, human papillomavirus (HPV) infection, and
p16
INK4a overexpression. The number of 53BP1 NF in
cervical cells appeared to increase with progression
during carcinogenesis. The distribution of 53BP1 NF
was similar to that of the punctate HPV signals as
determined by in-situ hybridization and also to p16
INK4a
overexpression in CIN, suggesting an association with
viral infection and replication stress.
Conclusions: Immunoﬂuorescence analysis of 53BP1
expression can be a useful tool with which to estimate
the level of GIN. During cervical carcinogenesis, GIN
may allow further accumulation of genomic altera-
tions, causing progression to invasive cancer.
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Any genotoxic agents can induce DNA damage and
consequently result in oncogenic alterations. The
importance of the DNA damage response (DDR) path-
way in tumour suppression is well recognized. A
defective DDR can result in genomic instability (GIN),
which is generally considered to be central to any
carcinogenic process.
1,2 Alternatively, the presence of
an activated DDR can be a hallmark of GIN, which may
subsequently enhance the carcinogenic process.
The p53-binding protein 1 (53BP1) belongs to a
family of evolutionarily conserved DDR proteins with C-
terminal BRCA1 C-terminus domains.
3,4 53BP1 is a
nuclear protein that rapidly localizes at the sites of DNA
double strand breaks (DSBs) and activates p53 along
with otherkinases.
5–10Activated p53 playscritical roles
in the DDR, such as cell cycle arrest, DNA repair, and
apoptosis.
11,12Ithasbeenwelldocumentedin vitrowith
immunoﬂuorescence that 53BP1 exhibits diffuse nucle-
ar staining in untreated primary cells, whereas, after
exposuretoradiation,53BP1localizesatthesitesofDSBs
and forms discrete nuclear foci (NF).
5,6,13,14 We have
recently demonstrated that, with an immunoﬂuores-
cence method, 53BP1 NF may serve as a valuable
molecular marker of GIN during carcinogenesis.
15,16
GIN seems to be induced at the precancerous stage
during thyroid and skin carcinogenesis, as follicular
adenoma and actinic keratosis show occasional 53BP1
NF.
15,16 Given that one manifestation of GIN is the
induction of endogenous DDR,
17 we propose that
immunoﬂuorescence analysis of 53BP1 expression can
beausefultoolwithwhichtoestimatethelevelofGINas
well as the malignant potential of human tumours.
Uterine cervical cancers are believed to develop
through a multistep process. Furthermore, it is well
established that persistent infections with high-risk
human papillomavirus (HR-HPV) represent a necessary
cause of high-grade premalignant lesions and subse-
quent invasive cancer of the uterine cervix. The HR-
HPV viral oncogenes, E6 and E7, have been shown to
be the main contributors to the development of human
papillomavirus (HPV)-induced cervical cancer, and
increased expression resulting from integration of the
viral DNA into the host genome has been detected in
invasive cancers and a subset of high-grade lesions.
18 It
has been shown that E6 and E7 together cause
polyploidy soon after they are introduced into cells, so
GIN is thought to play an essential role in the cellular
transformation of cervical epithelium during carcino-
genesis. The most manifest function of the E6 protein is
to promote the degradation of p53 through its inter-
action with a cellular protein, E6-associated protein, an
E3 ubiquitin ligase.
19 E7 is known to bind to the
retinoblastoma tumour suppressor gene product, reti-
noblastoma protein (pRb). Phosphorylation of pRb by
G1 cyclin-dependent kinases releases E2F, leading to
cell cycle progression into the S phase. E7 is able to
bind unphosphorylated pRb, and this may induce cells
to prematurely enter the S phase by disrupting pRb–
E2F complexes. One cyclin-dependent kinase inhibitor,
p16
INK4a, which prevents the phosphorylation of pRb
family members, is overexpressed when pRb is inacti-
vated by E7.
20 Normally, overexpression of p16
INK4a
results in cell cycle arrest, but with E7 expression, this
is overcome. Thus, overexpression of p16
INK4a has been
suggested as a useful biomarker for evaluating HPV
pathogenic activity in cervical lesions.
The present study analysed the presence of endog-
enous DSBs by immunoﬂuorescence for 53BP1 expres-
sion in a series of cervical tissues from patients to
evaluate the signiﬁcance of GIN and its association
with HPV infection and p16
INK4a overexpression dur-
ing cervical carcinogenesis. Like other tumours, GIN
was shown to be induced in cervical epithelium at a
precancerous stage, and increased signiﬁcantly with
progression to cancer.
Materials and methods
cervical lesions
Eighty archival uterine cervical tissue samples were
selected for this study from the archives of the
Department of Obstetrics and Gynaecology, University
Hospital. Accuracy of diagnosis was conﬁrmed by a
gynaecological pathologist (H.N.) and a general pathol-
ogist (M.N.). Histologically, the 80 primary cervical
tissue samples were as follows: 11 normal cervical
tissue samples from uteri that were surgically resected
because of leiomyoma; and 16 cervical intraepithelial
neoplasia (CIN)1, 15 CIN2, 24 CIN3 and 14 squamous
cell carcinoma (SCC) samples. All samples were forma-
lin-ﬁxed and parafﬁn-embedded tissues, from which
sections were prepared for immunoﬂuorescence and
in-situ hybridization (ISH) studies.
ish to detect hr-hpv
ISH was performed with the GenPoint Catalyzed Signal
Ampliﬁcation System (Dako, North America, Inc.,
Carpinteria, CA, USA) for HR-HPV (types 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; code
Y1443), according to the manufacturer’s protocols.
After deparafﬁnization and rehydration, the sections
were incubated in 0.8% pepsin for 10 min at 37 C and
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Sections were immersed in 0.3% H2O2 in methanol
for 20 min, and denatured and hybridized in a
humidiﬁed chamber at 37 C for 60 min. Detection of
hybridized probe was performed with the GenPoint
Tyramide Signal Ampliﬁcation System for Biotiny-
lated Probes (Dako North America, Inc.), with applica-
tion of primary peroxidase-conjugated streptavidin,
biotinyl-tyramide secondary peroxidase-conjugated
streptavidin, and the chromogenic substrate diam-
inobenzidine (DAB). The slides were counterstained
with haematoxylin. Evaluation of the HPV ISH signals
was performed according to the criteria described
previously.
21–23 In brief, the patterns were as follows:
(i) a diffuse pattern representing episomal HPV that
correlates with viral replication; (ii) a punctate pattern
consisting of one or a few discrete signals in the
nucleus, indicating HPV integration into the cellular
genome; and (iii) a mixed pattern with separate areas
containing only integrated or episomal copies, and
areas where the integrated virus was hidden in
episomal HPV copies.
immunofluorescence for 53bp1 expression
After antigen retrieval with microwave treatment in
citrate buffer, deparafﬁnized sections were preincubated
with 10% normal goat serum. Tissue sections were
then reacted with anti-53BP1 rabbit polyclonal anti-
body (Bethyl Labs, Montgomery, TX, USA) at a 1:200
dilution. The slides were subsequently incubated with
Alexa Fluor 488-conjugated goat anti-rabbit antibody
(Invitrogen, Carlsbad, CA, USA). Specimens were
counterstained with 4¢,6-diamidino-2-phenylindole
dihydrochloride (DAPI-I; Vysis, Downers Grove, IL,
USA), analysed, and photographed with a High Stan-
dard All-in-One Fluorescence Microscope (Biorevo BZ-
9000; Keyence Japan, Osaka, Japan). Signals were
analysed at a ·1000 magniﬁcation.
evaluation of immunofluorescence results
A human cervical cancer cell line, HeLa, was also
analysed by immunoﬂuorescence for 53BP1 expres-
sion. HeLa cells were cultured in RPMI-1640 medium
A B
Stable Low DDR High DDR Large foci
Figure 1. A, four types of p53-binding protein 1 (53BP1) expression found in HeLa cells: (1) stable type – faint and diffuse nuclear staining;
(2) low DNA damage response (DDR) type – one or two discrete nuclear foci (NF); (3) high DDR type – three or more discrete NF; and (4) large
NF type – discrete NF that are larger than 1.0 lm. B, measurements of the size of NF in a cell by use of a High Standard All-in-One
Fluorescence Microscope (Biorevo BZ-9000; Keyence Japan). 1, 1.01 lm; 2, 1.05 lm; 3, 0.53 lm.
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at 37 C in a 5% CO2 ⁄ 95% air environment. After
ﬁxation with methanol and preincubation with 10%
normal goat serum, cultured cells were treated accord-
ing to the same immunoﬂuorescence method as men-
tioned above. The pattern of 53BP1 immunoreactivity
was classiﬁed into four types (Figure 1): (1) stable type
– faint and diffuse nuclear staining; (2) low DDR type –
one or two discrete NF; (3) high DDR type – three or
more discrete NF; and (4) large NF type – discrete NF
that are larger than 1.0 lm. The percentage of cervical
epithelial cells expressing each type of 53BP1 immu-
noreactivity was calculated in each cervical lesion.
dual immunofluorescence for 53bp1
expression and ish to detect hr-hpv
To assess the association between localization of 53BP1
NF and HR-HPV integration into the host genome in
neoplastic cells, dual immunoﬂuorescence for 53BP1
expression and ISH to detect HR-HPV were performed
on the same tissue sections. Each section was ﬁrst
labelled by immunoﬂuorescence, subjected to ISH as
mentioned above, and photographed with a High
Standard All-in-One Fluorescence Microscope (Biorevo
BZ-9000; Keyence Japan). The images obtained were
merged and analysed by use of the accompanying
image analysis software with Biorevo BZ-9000.
immunohistochemistry for p16
ink4a expression
After immersion in 0.3% H2O2 ⁄ methanol, sections
were preincubated with 10% normal goat serum. After
antigen retrieval, tissues were incubated overnight at
4 C puriﬁed mouse anti-human p16 (BD Biosciences
Pharmingen, San Diego, CA, USA) at a 1:300 dilution.
The slides were subsequently incubated with biotiny-
lated goat anti-rabbit antibody for 1 h at room
temperature, and then avidin–peroxidase, and then
visualized with DAB.
double-label immunofluorescence
We also carried out double-label immunoﬂuorescence
staining for 53BP1 and Ki67 expression to clarify the
association between type of 53BP1 expression and
cyclingecells. For double staining, tissues were incu-
bated with a mixture of rabbit anti-53BP1 and mono-
clonal mouse anti-Ki67 (MIB-1; DakoCytomation)
antibodies at 1:50 dilutions, and subsequently incu-
bated with a mixture of Alexa Fluor 488-conjugated
goat anti-rabbit and Alexa Fluor 546-conjugated goat
anti-mouse antibodies. Specimens were counterstained
with DAPI-I (Vysis), and visualized and photographed
with a High Standard All-in-One Fluorescence Micro-
scope (Biorevo BZ-9000; Keyence Japan). Signals were
analysed at a ·1000 magniﬁcation.
statistical analysis
The Jonckheere–Terpstra test was used to assess
associations between the type of HPV ISH signal
(negative, diffuse, mixed diffuse and punctate, and
punctate) or the type of 53BP1 expression (stable, low
DDR, high DDR, and large NF) and histological grade of
cervical neoplasia. Associations between the types of
53BP1 expression and HPV ISH signal were also
assessed with the Jonckheere–Terpstra test. The PHREG
procedure in the SAS 8.2 software (SAS Institute, Cary,
NC, USA) was utilized for calculation. All tests were
two-tailed, and a P-value of <0.05 was accepted as
statistically signiﬁcant.
Table 1. Summary of high-risk human papillomavirus (HPV) in-situ hybridization (ISH) signal in the subjects used in this study
n
Mean age
[years (range)]
Type of HPV ISH signal, no. (%)
Negative Diffuse Mixed Punctate
Normal 11 42 (36–45) 11 (100) 0 0 0
CIN1 16 39 (18–68) 9 (56.3) 3 (18.8) 2 (12.5) 2 (12.5)
CIN2 15 36 (27–50) 3 (20) 3 (20) 3 (20) 6 (40)
CIN3 24 38 (28–62) 1 (4.2) 3 (12.5) 9 (37.5) 11 (45.8)
SCC 14 57 (31–76) 0 1 (7.1) 4 (28.6) 9 (64.3)
CIN, cervical intraepithelial neoplasia, SCC, squamous cell carcinoma.
P < 0.0001, Jonckheere–Terpstra test.
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hr-hpv ish signal in cervical lesions
The ISH results for each type of cervical lesions are
summarized in Table 1. Representative types of ISH
signals are illustrated in Figure 2. All normal cervical
epithelium cases were negative for HPV ISH signals. Of
the 16 CIN1 cases, nine (56.3%) expressed no signals,
three (18.8%) expressed the diffuse type, and two
(12.5%) were of the mixed and punctate type. Of the 15
CIN2 cases, three (20%) were of the negative and
diffuse type, three (20%) were of the mixed type, and
six (40%) were of the punctate type. Of the 24 CIN3
cases, only one (4.2%) was negative, three (12.5%)
were of the diffuse type, nine (37.5%) were of the mixed
type, and 11 (45.8%) were of the punctate type. All of
the 14 SCC cases were positive for HPV ISH signal: four
(28.6%) were of the mixed type and nine cases (64.3%)
were of the punctate type, whereas only one (7.1%)
expressed the diffuse type. Statistical analysis revealed
signiﬁcant associations between type of HPV ISH signal
and type of cervical lesion (P < 0.0001). The incidence
of mixed and punctate types signiﬁcantly increased in
the order of normal, CIN1, CIN2, CIN3, and SCC.
53bp1 expression in cervical lesions
The results of the immunoﬂuorescence staining pat-
terns for 53BP1 in cervical lesions are presented in
Table 2, and typical examples are depicted in Figure 3.
Quantitation of the signals revealed immunopositivity
in 4877 nuclei (443.4 nuclei per case) in normal
cervical epithelium, 10 483 nuclei (655.2 nuclei per
case) in CIN1, 9976 nuclei (665.1 nuclei per case) in
CIN2, 14 953 nuclei (623.0 nuclei per case) in CIN3,
and 7979 nuclei (569.9 nuclei per case) in SCC. In the
normal cervical epithelium, 95.8% of nuclei showed
the stable type, and only 4.3% of nuclei showed the
DDR type. In CIN1, 73.4% of nuclei showed the stable
type, and 25.2% and 1.4% of nuclei showed the DDR
and large NF types, respectively. In CIN2, 58.4% of
nuclei showed the stable type, and 38.1% and 3.5% of
nuclei showed the DDR and large NF types, respec-
tively. In CIN3, 33.7% of nuclei showed the stable type,
and 58.5% of nuclei showed DDR types, including
37.5% with the high DDR type and 7.8% with the large
NF type. Finally, in SCC, only 18.3% of nuclei showed
the stable type, and 65.6% of nuclei showed DDR types,
including 49.8% with the high DDR type and 16.2% of
nuclei with the large NF type. The statistical analysis
ABC
Figure 2. In-situ hybridization signals of high-risk human papillomavirus in cervical lesions. Signal types were classiﬁed as diffuse [A,
cervical intraepithelial neoplasia (CIN)1], mixed (B, CIN2), or punctate (C, CIN3). Arrows in the inset of B indicate punctate signals.
Table 2. Results for type of p53-binding protein 1 (53BP1) expression in cervical lesions by immunoﬂuorescence
n
Counted
nuclei
Type of 53BP1 expression (%)
Stable Low DDR High DDR Large foci
Normal 11 4877 95.8 3.1 1.2 0.0
CIN1 16 10 483 73.4 15.0 10.2 1.4
CIN2 15 9976 58.4 19.0 19.1 3.5
CIN3 24 14 953 33.7 21.0 37.5 7.8
SCC 14 7979 18.3 15.8 49.8 16.2
CIN, cervical intraepithelial neoplasia; DDR, DNA damage response; SCC, squamous cell carcinoma.
P < 0.0001, Jonckheere–Terpstra test.
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was signiﬁcantly associated with type of 53BP1
expression (P < 0.0001).
association between 53bp1 nf and hr-hpv ish
signals in cervical epithelium
Associations between types of 53BP1 expression and
HR-HPV ISH signal in the cervical epthelium are
summarized in Table 3. In the cervical epithelium with
negative HR-HPV ISH signal, 78.5% of nuclei showed
the stable type, and 20.5% of nuclei showed the DDR
type. In the cervical epithelium with the diffuse type of
HR-HPV ISH signal, 55.6% of nuclei showed the stable
type, and 42.1% and 2.4% of nuclei showed the DDR
and large NF types, respectively. In the cervical
epithelium with the mixed type of HR-HPV ISH signal,
39.3% of nuclei showed the stable type, and 51.2% and
9.6% of nuclei showed the DDR and large NF types,
respectively. Finally, in the cervical epithelium with the
A B C
D E F
Figure 3. Immunoﬂuorescence for p53-binding protein 1 (53BP1) expression in cervical lesions. Normal cervical epithelium (A) expressed
the stable type of staining, with rare, one or two nuclear foci (NF), whereas cervical intraepithelial neoplasia (CIN)1 (B) and CIN2 (C)
occasionally expressed three or more NF in dysplastic cells at the basal layer. CIN3 showed several discrete NF (D) with occasional large
foci (E) throughout the epithelium. Squamous cell carcinoma (F) showed several discrete NF including large foci.
Table 3. Association between types of p53-binding protein 1 (53BP1) expression and human papillomavirus (HPV) in-situ
hybridization (ISH) signal in cervical epithelium
Type of HPV ISH signal n
Type of 53BP1 expression (%)
Stable Low DDR High DDR Large foci
Negative 24 78.5 12.6 7.9 1.0
Diffuse 10 55.6 17.7 24.4 2.4
Mixed 18 39.3 20.4 30.8 9.6
Punctate 28 35.1 18.4 35.9 10.6
DDR, DNA damage response.
P < 0.0001, Jonckheere–Terpstra test.
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showed the stable type, and 54.3% of nuclei showed
DDR types, including 35.9% with the high DDR type
and 10.6% with the large NF type. The statistical
analysis revealed that the type of HR-HPV ISH signal in
cervical neoplasms was signiﬁcantly associated with
type of 53BP1 expression (P < 0.0001). The incidence
of the DDR and large NF types signiﬁcantly increased in
the order of negative, diffuse, mixed and punctate types
of HR-HPV ISH signal.
The results of the dual immunoﬂuorescence staining
for 53BP1 expression and ISH to detect HR-HPV are
shown in Figure 4. In CIN showing the mixed type of
HR-HPV ISH signal, 53BP1 NF and the punctate type
of HR-HPV ISH signal were similarly distributed in the
dysplastic cells at the basal portion in cervical epithe-
lium. Also in SCC showing the punctate type of HR-
HPV ISH signal, 53BP1 NF and the punctate type of
HR-HPV ISH signal were similarly distributed through-
out the cancer cells. However, co-localization of 53BP1
NF and the punctate type of HR-HPV signal was very
rare.
association between 53bp1 and p16
ink4a
expression in cervical lesions
The comparison of 53BP1 expression and p16
INK4a
expression in cervical lesions is shown in Figure 5. The
distribution of 53BP1 NF matched p16
INK4a overex-
pression in each cervical lesion.
double-label immunofluorescence staining
for 53bp1 and ki67
CIN1 expressed the stable or low DDR type of 53BP1
immunoreactivity, and little Ki67 nuclear staining,
mainly at the basal layer (Figure 6). In contrast, a high
level of the DDR and large NF type of 53BP1 expression
and several nuclei showing Ki67 staining were
observed in CIN3 and SCC cells. Furthermore, double
staining for 53BP1 and Ki67 demonstrated that NF of
53BP1 immunostaining were not co-localized with
Ki67-positive dysplastic cells in CIN3, whereas 53BP1
NF-positive cells frequently expressed Ki67 nuclear
staining in SCC.
Discussion
Ionizing radiation (IR) effectively induces DSBs in
normal cells and activates DDR pathways to maintain
genomic integrity. Although non-irradiated cells typi-
cally show diffuse 53BP1 nuclear staining, many
53BP1 NF are immediately induced after exposure to
a low dose of IR.
13 Schultz et al.
6 showed that the
number of 53BP1 NF induced by IR increased linearly
with the dose of IR. On the other hand, we found that
HeLa cells express occasional discrete 53BP1 NF
without any genotoxic treatments, suggesting the
occurrence of endogenous DSBs in cancer cells. One
manifestation of GIN is induction of endogenous
DSBs;
17 thus, the level of 53BP1 NF formation can be
AB
Figure 4. Dual immunoﬂuorescence for p53-binding protein 1 (53BP1) expression (green) and in-situ hybridization (ISH) signals of high-risk
human papillomavirus (red). The distribution of 53BP1 nuclear foci (NF) was the same as that of the punctate type of ISH signal in both cervical
intraepithelial neoplasia (CIN)1 with the mixed type (A) and squamous cell carcinoma with punctate type (B) of ISH signal. However,
co-localization of 53BP1 NF and the punctate type of ISH signal was very rare. Arrows indicate co-localization of 53BP1 NF and the punctate
type of ISH signal.
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Figure 5. Comparison of p53-binding protein 1 (53BP1) (A,C,E,G) and p16
INK4a expression (B,D,F,H) in semi-serial sections of
cervical lesions. The distribution of 53BP1 nuclear foci was similar to that of p16
INK4a overexpression in normal (A,B), cervical
intraepithelial neoplasia (CIN1) (C,D), CIN2 (E,F), and squamous cell carcinoma (G,H).
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present study has clearly demonstrated that the num-
ber of discrete NF (DDR type) of 53BP1 in cervical cells
increases with tumour progression, as seen by the
normal–CIN1–CIN2–CIN3–SCC sequence. The number
of discrete NF in the DDR type of 53BP1 NF in the
cervical epithelium seems to increase in precancerous
lesions, and the high DDR type and large NF type of
53BP1 immunoreactivity are predominantly observed
in SCC. Similar results, showing the differences in
53BP1 expression patterns during carcinogenesis, were
obtained in our previous studies on thyroid and skin
tumours resected from patients.
15,16 Therefore, we
propose that immunoﬂuorescence analysis of 53BP1
expression can be a useful tool with which to estimate
the level of GIN as well as the malignant potential of
several human tumours.
The value of p16
INK4a as a surrogate marker of HR-
HPV and CIN has been well established in recent years,
with studies showing both increased immunoexpres-
sion of p16
INK4a in dysplastic cervical epithelium and a
positive correlation with HR-HPV infection and the
degree of CIN.
24–30 Cervical SCC develops through a
multistep process that involves replication stress. An
important occurrence in cervical carcinogenesis is
deregulated expression of the HR-HPV oncogenes E6
and E7. Several risk factors for cervical neoplastic
progression are likely to contribute to viral oncogene
deregulation, particularly integration of HR-HPV into
the host genome.
31,32 We found a signiﬁcant associa-
A B C
D E F
G H I
Figure 6. Double-label immunoﬂuorescence staining for p53-binding protein 1 (53BP1) (green) and Ki67 expression (red) in cervical lesions.
Cervical intraepithelial neoplasia (CIN)1 showed no or a few nuclear foci (NF) of 53BP1 immunoreactivity and little Ki67 nuclear staining,
mainly at the basal layer (A–C). CIN3 showed several 53BP1 NF that were independent of Ki67 nuclear staining in cancer cells (D–F). Squamous
cell carcinoma showed nuclei with both 53BP1 NF and Ki67 immunoreactivity (G–I), suggesting disruption of the DNA damage response
pathway.
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53BP1 expression in the cervical epithelium. The
distribution of 53BP1 NF was similar to that of the
punctate type of ISH signals in both CIN and SCC,
suggesting that viral integration could induce endog-
enous DSBs through the induction of GIN in the host
genome. Furthermore, in cervical lesions, the distribu-
tion of 53BP1 NF was identical to that of p16
INK4a
overexpression; this represents a byproduct of viral
infection, and suggests an association between the
presence of GIN and replication stress that allows
enhancement of cell proliferation and avoidance of cell
death. As co-localization of 53BP1 NF and the punctate
type of HR-HPV ISH signal was rare, most viral
integrated sites might have been bypassed by the host’s
DDR machinery, and integrants may have a growth
advantage over others in a mixed population of cervical
cells.
This study also demonstrated little co-localization of
the DDR type of 53BP1 expression and Ki67 nuclear
staining as a marker for cycling cells in precancerous
lesions. An intact DDR pathway is activated, leading to
cell cycle arrest by p53 activity, so precancerous ⁄ dys-
plastic cells may still preserve DDR function, at least
partially, and this may induce sporadic regression of
dysplasia. In contrast, cancer cells showing 53BP1 NF
were frequently co-localized with Ki67 staining, sug-
gesting a disruption of the DDR pathway that subse-
quently leads to an irreversible malignant
transformation. Taken together, these ﬁndings indicate
that GIN may have already occurred at the precancer-
ous stage during cervical carcinogenesis, and that
increasing GIN based on a disrupted DDR may allow
further accumulation of other genomic alterations,
causing progression to invasive cancer through accel-
eration of cell growth ⁄ replication stress. Further
research is needed on the molecular mechanism of
the uncoupling of cell cycle progression in the face of
increasing severity of DNA damage at the advanced
phase of carcinogenesis.
In summary, this study has demonstrated a number
of 53BP1 NF in cervical lesions resected from patients
that were similar to those found in irradiated cells with
a DDR pathway activated to eliminate DSBs, suggesting
the occurrence of endogenous DSBs. GIN seems to be
induced at the precancerous stage through integration
of the HR-HPV genome into the host cell genome.
Furthermore, invasive cancers exhibited 53BP1 NF in
cycling cells, which suggested that the disrupted DDR
subsequently led to further ampliﬁcation of the geno-
mic injury. A recent study on immunohistochemical
detection of DDR-associated molecules, including
53BP1, suggests that GIN is an early event that occurs
in pulmonary hyperplasia prior to changes in the p53
tumour suppressor gene during lung carcinogenesis in
patients, suggesting that GIN may serve as a causative
link between precancer and cancer.
33 Thus, measure-
ment of GIN, a hallmark feature of solid tumours that is
implicated in both the initiation and progression of
cancers, may serve as a valuable molecular marker of
malignant potential. Our recent study also demon-
strated that the detection of 53BP1 NF by immunoﬂu-
orescence can be a useful histological marker with
which to estimate the malignant potential of thyroid
and skin tumours.
15,16 Thus, we propose that immu-
noﬂuorescence analysis of 53BP1 expression can be a
useful tool with which to estimate the level of GIN and,
simultaneously, the stage of cancerous progression of
uterine cervical lesions.
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